1.77
price down icon5.85%   -0.11
after-market 시간 외 거래: 1.79 0.02 +1.13%
loading
전일 마감가:
$1.88
열려 있는:
$1.82
하루 거래량:
230.00K
Relative Volume:
1.25
시가총액:
$177.73M
수익:
-
순이익/손실:
$-60.14M
주가수익비율:
-2.4947
EPS:
-0.7095
순현금흐름:
$-68.17M
1주 성능:
-11.50%
1개월 성능:
-26.25%
6개월 성능:
-47.79%
1년 성능:
-36.79%
1일 변동 폭
Value
$1.77
$1.86
1주일 범위
Value
$1.77
$2.00
52주 변동 폭
Value
$1.77
$4.9782

Ac Immune Sa Stock (ACIU) Company Profile

Name
명칭
Ac Immune Sa
Name
전화
-
Name
주소
-
Name
직원
172
Name
트위터
@AC_Immune_SA
Name
다음 수익 날짜
2024-11-18
Name
최신 SEC 제출 서류
Name
ACIU's Discussions on Twitter

ACIU을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ACIU
Ac Immune Sa
1.77 177.73M 0 -60.14M -68.17M -0.7095
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Ac Immune Sa Stock (ACIU) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-05-31 개시 BTIG Research Buy
2019-02-01 다운그레이드 UBS Buy → Neutral
2019-01-04 개시 UBS Buy
2018-04-05 개시 H.C. Wainwright Buy
2018-03-23 다운그레이드 Credit Suisse Outperform → Neutral
2016-10-18 개시 Credit Suisse Outperform
2016-10-18 개시 Jefferies Buy
2016-10-18 개시 Leerink Partners Outperform
모두보기

Ac Immune Sa 주식(ACIU)의 최신 뉴스

pulisher
06:11 AM

AC Immune reports Phase II trial of ACI-7104.056 - The Pharma Letter

06:11 AM
pulisher
Apr 02, 2025

AC Immune’s Strategic Advances and Financial Highlights - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune (ACIU) Shares Surge on Promising Parkinson's Trial Res - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune stock gains on Parkinson’s data (ACIU:NASDAQ) - Seeking Alpha

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune announces additional data from Phase 2 study of VacSYn clinical trial - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune SAACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune Reports Further Positive Interim Results from - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - GlobeNewswire Inc.

Apr 02, 2025
pulisher
Apr 01, 2025

Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet - simplywall.st

Apr 01, 2025
pulisher
Mar 25, 2025

AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı

Mar 25, 2025
pulisher
Mar 25, 2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

ACIUAC Immune Latest Stock News & Market Updates - Stock Titan

Mar 25, 2025
pulisher
Mar 18, 2025

Promising Developments in AC Immune SA’s ACI-7104 Program Drive Buy Rating - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

AC Immune: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks

Mar 17, 2025
pulisher
Mar 16, 2025

AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago - Yahoo Finance

Mar 16, 2025
pulisher
Mar 16, 2025

AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 16, 2025
pulisher
Mar 13, 2025

AC Immune SA reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

AC Immune SA Reports 2024 Financial Results and Strategic Advances - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

AC Immune reports FY24 EPS (51c), consensus (54c) - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

AC Immune SA Reports 2024 Financial Results and Announces Takeda Partnership for ACI-24.060 - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

AC Immune Lands Massive $2.1B Potential Deal with Takeda, Extends Cash Runway to 2027 - StockTitan

Mar 13, 2025
pulisher
Mar 06, 2025

AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

New Strong Buy Stocks for March 5th - Nasdaq

Mar 05, 2025
pulisher
Mar 04, 2025

AC Immune to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

AC Immune Management Team Opens Door to Investors at Two Major Healthcare Conferences - StockTitan

Mar 04, 2025
pulisher
Feb 19, 2025

AC Immune: Leader In Dementia Therapies, A Space Littered With Failures (ACIU) - Seeking Alpha

Feb 19, 2025
pulisher
Feb 15, 2025

Contrasting Silence Therapeutics (NASDAQ:SLN) & AC Immune (NASDAQ:ACIU) - Defense World

Feb 15, 2025
pulisher
Feb 13, 2025

Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News

Feb 13, 2025
pulisher
Feb 13, 2025

AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. To Its Board - citybiz

Feb 13, 2025
pulisher
Feb 13, 2025

Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) - Yahoo Finance

Feb 13, 2025
pulisher
Feb 12, 2025

AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors - Business Wire

Feb 12, 2025
pulisher
Feb 04, 2025

Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

3 US Penny Stocks With Market Caps Over $100M To Consider - Simply Wall St

Feb 03, 2025
pulisher
Feb 01, 2025

Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

New Strong Buy Stocks for January 31st - Yahoo Finance

Jan 31, 2025
pulisher
Jan 29, 2025

Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - Neurology Live

Jan 29, 2025
pulisher
Jan 24, 2025

Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media

Jan 24, 2025
pulisher
Jan 22, 2025

AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World

Jan 22, 2025
pulisher
Jan 17, 2025

Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Roche, Aelis Farma, AC Immune SA, Eisai Inc., Forest Lab, Eisai Co. - The Globe and Mail

Jan 17, 2025
pulisher
Jan 17, 2025

Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA - openPR

Jan 17, 2025
pulisher
Jan 17, 2025

AC Immune (NASDAQ:ACIU) Shares Cross Below Fifty Day Moving AverageTime to Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Micron Technology (MU-Q) QuotePress Release - The Globe and Mail

Jan 16, 2025
pulisher
Jan 09, 2025

Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight - The Malaysian Reserve

Jan 09, 2025
pulisher
Jan 09, 2025

AC Immune (NASDAQ:ACIU) Shares Down 4.4%Here's What Happened - MarketBeat

Jan 09, 2025
pulisher
Jan 03, 2025

US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Simply Wall St

Jan 03, 2025

Ac Immune Sa (ACIU) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):